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Abstract
Background: Type 1 diabetes (T1D) is an autoimmune disease resulting from defects in central and peripheral tolerance and
characterized by T cell-mediated destruction of islet b cells. To determine whether specific lysosomal proteases might
influence the outcome of a T cell–mediated autoimmune response, we examined the functional significance of cathepsin
inhibition on autoimmune T1D-prone non-obese diabetic (NOD) mice.
Methods and Findings: Here it was found that specific inhibition of cathepsin L affords strong protection from
cyclophosphamide (CY)-induced insulitis and diabetes of NOD mice at the advanced stage of CD8
+ T cell infiltration via
inhibiting granzyme activity. It was discovered that cathepsin L inhibition prevents cytotoxic activity of CD8
+ T cells in the
pancreatic islets through controlling dipeptidyl peptidase I activity. Moreover, the gene targeting for cathepsin L with
application of in vivo siRNA administration successfully prevented CY-induced diabetes of NOD mice. Finally, cathepsin L
mRNA expression of peripheral CD8
+ T cells from NOD mice developing spontaneous T1D was significantly increased
compared with that from control mice.
Conclusions: Our results identified a novel function of cathepsin L as an enzyme whose activity is essential for the
progression of CD8
+ T cell-mediated autoimmune diabetes, and inhibition of cathepsin L as a powerful therapeutic strategy
for autoimmune diabetes.
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Introduction
The cathepsins constitute a family of lysosomal proteases that
are recognized as non-specific scavengers to recycle cellular
proteins within lysosomes, and that are also found to display cell
type–specific functions [1–5]. Although the action of lysosomal
proteases is not necessarily limited to the endosomal system for
antigen processing, it remains obscure in that the in vivo activity of
lysosomal proteases regulates the peripheral immune responses.
Studies of gene-knockout mice or specific inhibitors for
cathepsins have demonstrated that the emzymatic activities of
cathepsins play key roles in the pathogensesis of autoimmune
diseases such as autoimmune myasthenia gravis, rheumatoid
arthritis, Sjogren’s syndrome, and autoimmune Type-1 diabetes
(T1D) [6–9]. As it was reported that cathepsin L-deficient NOD
mice are protected from insulitis and diabetes due to the increased
number of regulatory T (Treg) cells in the periphery through the
defective thymic selection [10], the therapeutic application with
cathepsin inhibitor may be clinically useful. However, it is still
unclear whether cathepsin L plays any role in peripheral effector
cells or cytotoxic cells other than Treg cells in the development of
autoimmune diabetes.
Here the role of cathepsin L in cyclophosphamide (CY)-
treated nonobese diabetic (NOD) mice, a model for spontaneous
T1D [11,12] using a cathepsin L-specific inhibitor was
investigated. It has been described that CY-induced T1D in
the NOD mouse is associated with a reduction of Treg cells
[13]. In cathepsin L-deficient mice and cathepsin L-deficient
NOD mice, the direct effect of cathepsin L on the peripheral T
cells has not been clarified; although it was demonstrated that
cathepsin L plays a key role in the T cell differentiation in the
thymus [10,13].
In this study, a novel function of cathepsin L as an enzyme
whose activity is essential for the progression of CD8
+ T cell-
mediated autoimmune diabetes was identified, and the specific
inhibition of cathepsin L as a powerful therapeutic strategy for
autoimmune diabetes was demonstrated.
Results
Effective Treatment of CY-induced T1D in NOD Mice by a
specific inhibitor of cathepsin L
A specific inhibitor of the cathepsin L (CatL-inh) [14,15] was
intraperitoneally (i.p.) administered into CY-treated NOD mice.
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12894Treatment with CatL-inh protected diabetes-prone NOD mice
from subsequently occurring diabetes such as high blood sugar and
urine sugar while there was no therapeutic effect of cathepsin B
inhibitor (CatB-inh) and cathepsin S inhibitor (CatS-inh)
(Figure 1A, B). To determine whether CatL-inh administration
is effective on the onset of insulitis, histological sections for the
presence of insulitis were analyzed. The histological finding of
islets from CY-treated NOD mice showed lymphocytic infiltration,
ranging from peri-insulitis to severe extensive, and atrophic or
damaged islets with a decrease in cell numbers (Figure 1D, E, F),
compared with that of control NOD mice (Figure 1C). In contrast,
CatL-inh protected severe insulitis and damage of islets, although
a slight inflammatory lesion with peri-insulitis was observed
(Figure 1G, H). Moreover, semiquantitative evaluation of islet
inflammation was performed using pancreatic sections from
control, CY-treated, and CY+CatL inh-treated NOD mice. The
histological score of CY-treated NOD mice was significantly
reduced by the administration of CatL inh (Figure 1I). This result
showed that cathepsin L plays an important role in the onset of
T1D in NOD mice as previously described [10], and that the
specific cathepsin L inhibitor may be useful for the effective
treatment of autoimmune diabetes.
Effects of CatL-inh Administration on Peripheral Immune
Cells
It was reported that an increased proportion of Treg cells in the
periphery of cahtepsin L-deficient NOD mice was observed
compared with that of controlNODmice[10]. When Foxp3
+CD4
+
Treg cells of pancreatic lymph nodes (PLN) in CY-treated and
control NOD mice were analyzed, the number of Treg cells of PLN
from CY-treated NOD mice was significantly reduced compared
with control NOD mice as previously reported [13]. On the other
hand, there was no increase in the number of Treg cells observed by
the administration of CatL-inh (Figure 2A). In addition, to evaluate
the effect of in vivo treatment with CatL-inh in CY-treated NOD
mice on APCs such as B cells and dendritic cells (DCs), the
expressions of MHC class II on the cells were detected by flow
cytometric analysis. The MHC class II expression on PLN B cells
from CY-treated NOD mice was increased compared with that
from control NOD mice (Figure 2B). The enhanced level of the
Figure 1. In Vivo Therapeutic Effect of Cathepsin L Inhibitor (CatL-inh) on T1D in CY-treated NOD Mice. (A, B) The blood glucose and
urine glucose levels were monitored weekly. Data are shown as means 6 s.d. of 4 or 5 mice in each group. *, P,0.05, and **, P,0.01. CY-treated mice
versus CatL-inh-treated mice. Results are representative of 4 or 5 mice in each group. (C, D, E, F, G, H) Histopathological analysis of islets control
(prediabetic) (C), CY-treated (D, E, F) and CY+CatL-inh-treated (G, H) NOD mice. Results are representative of 4 or 5 mice in each group. (I) Histological
score of islets from control (n=5), CY-treated (n=4) and CY+CatL-inh-treated (n=5) NOD mice. Data are shown as histological score of individual
islets.
doi:10.1371/journal.pone.0012894.g001
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PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12894Figure 2. The Effects of CatL-inh Administration on Immune Cells in CY-induced T1D. (A) Flow cytometric analysis was performed to
detect intracellular Foxp3 in CD4
+ T cells of pancreatic lymph nodes (PLNs) from control mice, CY-treated mice and CY+CatL-inh-treated mice. (B, C)
CD44 expressions on CD4
+ and CD8
+ T cells in PLNs from control, CY-treated, and CY+CatL-inh-treated mice were analyzed by flow cytometry. Results
are representative of 3 to 5 mice in each group. (D) Enzymatic activities of cathepsin L in thymus and PLNs from control and CY-treated NOD mice. (E)
The mRNA expressions of cathepsin L were detected by real-time PCR using purified CD8
+, CD4
+, CD4
+CD25
+, B220
+ and CD11c
+ cells of PLNs from
NOD mice. Data are shown as means 6 s.d. of 3 to 4 mice in each group.
doi:10.1371/journal.pone.0012894.g002
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administration of CatL-inh (Figure 2B). Also, there was no
difference in the expression level of MHC class II on DCs between
CY-treated and CY+CatL-inh-treated NOD mice (Figure 2B).
Although cathepsin L is well known to be one of the key proteases in
the antigen processing of APCs of the thymus [10], it is still unclear
whether cathepsin L plays any roleinthe peripheralAPCs such as B
cells and DCs of lymph nodes. To further investigate whether
cathepsin L inhibition influences the antigen processing and
presentation, an in vitro experiment using ovalbumin (OVA)-specific
T cell receptor (TCR)-transgenic mice (OT-II) was conducted. In
brief, purified CD4
+ T cells from the spleen of OT-II mice were
labeled with carboxyfluorescein diacetate succinimidyl ester
(CFSE), and co-cultured with T cell-depleted spleen cells as APCs
from B6miceinthe presence ofOVAproteinwithorwithout CatL-
inh or CatS-inh for three days. A small inhibitory effect of CatL-inh
(0.05, 0.5 mM) on OT-II T cell response to OVA was observed
although inhibitory effect of CatL-inh at high concentration (5 mM)
on the T cell response was found (Figure S1). In contrast, CatS-inh
more effectively inhibited the proliferative response compared with
the effect of CatL-inh, indicating that cathepsin S, rather than
cathepsin L, plays a crucial role in antigen processing and
presentation of APCs. The in vivo experiment using the CatL-inh
suggested that there may be no direct effect of cathepsin L on the
APCs during the pathogenesis of T1D in NOD mice. Moreover, to
examine the effect of CatL-inh administration on T cell activation,
CD44 expression, an activation marker, was analyzed using PLN T
cells. The enhanced activation of CD8
+, not CD4
+ T cells in CY-
treated NOD mice was suppressed by the CatL-inh administration
(Figure 2C). Furthermore, as shown in Figure 2D, the enzymatic
activities of cathepsin L of PLN cells from CY-treated NOD mice
was significantly higher than that from control NOD mice.
Additionally, we investigated endogenous cathepsin L mRNA levels
among various immune cell populations of PLN from NOD mice.
The highest expression of cathepsin L mRNA was observed in
CD8
+ T cells (Figure 2E).On the other hand, as shown in Figure 2E
and Figure S1, the expression of cathepsin L mRNA of PLN CD8
+
T cells from NOD mice was significantly higher than that from
normal age-matched C57BL/6J mice (B6: 1.2860.13, NOD:
3.260.46610
23 to b-actin mRNA expression, p,0.05). By
contrast, the expression levels of CD4
+, CD25
+CD4
+, B220
+ B,
and CD11c
+ cells from NOD mice were similar to the levels of B6
mice (Figure S2). Among the immune cells of B6 mice, the
expression levels of CD8
+ T cells and DCs were considerably
increased compared with those of CD4
+, CD25
+CD4
+ and B220
+
cells (Figure S2). We suggest that this change in the CD8
+ T cells
may account for the protection of diabetes observed in CatL-inh-
treated NOD mice.
Cathepsin L in CD8 T Cells of CY-treated NOD Mice
Next, the role of cathepsin L of CD8
+ T cells in the pancreas
tissues from CY-treated NOD mice was analyzed. Immunofluo-
rescence staining showed an increased infiltration of CD8
+ T cells
in the islets from CY-treated NOD mice compared to that from
control NOD mice (Figure 3A, right panel). In control NOD mice
in which peri-insulitis was observed, the majority of infiltrating
lymphocytes was CD4
+ T cells, plus a small number of CD8
+ T
cells (Figure 3A, left panel). Additionally, flow cytometric analysis
indicated that there was a significantly increased number of CD8
+
T cells as well as CD4
+ T cells in the pancreas tissues and PLNs
from CY-treated NOD mice compared with control NOD mice
(Figure 3B). Multiple lines of study have demonstrated the
importance of CD8
+ T cells in the pathogenesis of T1D in
NOD mice and T1D patients [16–18]. To detect the enzymatic
activity of cathepsin L of the infiltrating CD8
+ T cells in the
pancreas tissues, flow cytometric analysis using the fluorogenic
substrates (Magic Red
TM) of cathepsin L was performed. A
significantly enhanced cathepsin L activity of pancreatic CD8
+ T
cells from CY-treated NOD mice was observed compared with
that from control NOD mice (Figure 3C). In PLNs, a slight
increased activity of cathepsin L in CD8
+ T cells from CY-treated
NOD mice was detected (Figure 3C). Moreover, to understand the
relationship between cytotoxic activity and enzymatic activity of
cathepsin L in CD8
+ T cells, both granzyme B expression and
cathepsin L enzymatic activity were analyzed by flow cytometry.
By CY-treatment, the cell numbers of granzyme B
+ CatL
+ CD8
+
T cells in both pancreas and PLNs were significantly increased
compared with those from control NOD mice (Figure 3D). These
results indicate that cathepsin L might control the cytotoxic
activity of CD8
+ T cells against the islets of pancreas in
autoimmune diabetes of NOD mice.
Effective Inhibition of CatL-inh on CTL Activity of CD8 T
Cells
To further investigate the cellular mechanism of CD8
+ T cell
activation through cathepsin L, in vitro experiments using purified
CD8
+ T cells from PLNs of NOD mice were performed. No toxic
effect of CatL-inh on CD8
+ T cells in this experiment was
observed (Figure S3). When the CD8
+ T cells were stimulated with
phorbol 12-myristate 13-acetate (PMA) and ionomycin (IM), the
increased level of enzymatic activity of cathepsin L was confirmed
by confocal analysis using Magic Red
TM (Figure 4A). Increased
granzyme B expression of CD8
+ T cells was observed with the
addition of PMA/IM. Then the enhanced expression level was
decreased by the addition of CatL-inh (Figure 4B). It has been
reported that dipeptidyl peptidase I (DPPI) is a granule protease
that plays a requisite role in processing the proenzyme form of the
cytotoxic T-lymphocyte (CTL) granule serine proteases (gran-
zymes) [19–22]. In addition to its role in the lysosomal protein
degradation, DPPI functions as a key enzyme in the activation of
granule serine peptidases in CTL [23]. Since it has been
demonstrated that cathepsin L could be an important activator
of DPPI from its precursor form in vitro [24], the enzymatic activity
of CD8
+ T cells from NOD mice was examined. DPPI enzymatic
activity of CD8
+ T cells was elevated by stimulation of PMA/IM,
and the addition of CatL-inh reduced the increased DPPI activity
(Figure 4C). Finally, it was examined whether cytotoxicity of the
activated CD8
+ T cells against the enriched islet cells is suppressed
by CatL-inh. The islet cells from pancreas of NOD mice were
isolated as described in Methods. Over 70% of the enriched islet
cells produced insulin (Figure S4A). To evaluate the toxic effect of
CatL-inh on the islet cells as target cells, the isolated islet cells were
incubated with CatL-inh for 24 hours. No change of apoptotic or
necrotic cells showing annexin-V and PI was observed by this
incubation (Figure S4B). CTL activity of CD8
+ T cells against the
target cells from pancreas of NOD mice was significantly
suppressed by CatL-inh (Figure 4D). Theses results indicated that
a simple mechanism of inhibiting the activities of DPPI by CatL-
inh could provide a powerful way to regulate the ability of immune
effector CD8
+ T cells to kill their targets.
Effective Therapy of CY-induced T1D by Small
Interference (si) RNA Targeting Cathepsin L Gene
To further confirm the effects of cathepsin L-inhibition, it was
examined whether injection of athelocollagen-mediated small
interference (si) RNA for cathepsin L gene silencing provides long-
term suppression of diabetes development in CY-treated NOD
Cathepsin L in Type 1 Diabetes
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+ T cells in T1D. (A) CD4 (red) and CD8 (green) T cells were shown by confocal microscopic
analysis. Nuclei were stained with DAPI. Plots depict 2.5 D graphical reconstructions of the green intensity profile of the imaged areas, illustrating
individual intensities per pixel utilizing the rainbow scale. (B) CD4
+ and CD8
+ T cells on lymphocytes in pancreas tissues and PLNs from control and
CY-treated mice were analyzed at one week after the second CY injection by flow cytometry. (C) Enzymatic activities of cathepsin L (Magic Red
TM)o f
CD8
+ T cells were detected by flow cytometric analysis using pancreas tissues and PLNs from control and CY-treated mice. (D) Association of
intracellular granzyme B expression with enzymatic activity of cathepsin L in CD8
+ T cells was evaluated by flow cytometric analysis using pancreas
tissues and PLNs from control and CY-treated mice. Results are representative of 3 to 4 mice in each group.
doi:10.1371/journal.pone.0012894.g003
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siRNA targeting cathepsin L (CatL siRNA) intraperitoneally (i.p.)
caused a marked decrease in the development of CY-induced
diabetes in NOD mice showing a high level of blood glucose
(Figure 5A). To confirm the effect of the Cat L-siRNA on the
expression of the target gene, mRNA expression of cathepsin L of
PLN CD8
+ T cells was quantified by real-time PCR. A reduced
expression of cathepsin L mRNA from CatL siRNA-treated mice
was observed compared with that from control siRNA-treated
mice (Figure 5B). Histological analysis showed that inflammatory
infiltration of lymphocytes and destructive changes in islets of the
pancreas tissues from CatL siRNA-treated mice were clearly
prevented in contrast to the severe inflammatory lesions of control
siRNA-treated mice (Figure 5C). Furthermore, the histological
score of infiltrates in islets from CatL siRNA-treated mice was
significantly reduced compared with that from control siRNA-
treated mice (Figure 5D). There were no differences in the cell
numbers of T cell populations of PLNs between CatL siRNA- and
control siRNA-treated mice (Figure S5). In addition, the
expression level of DPPI mRNA of PLN CD8
+T cells from CatL
siRNA-treated mice was lower than that from control siRNA-
treated mice (Figure 5E). These results demonstrated that the gene
targeting of cathepsin L by in vivo administration of siRNA may be
one therapeutic strategy for autoimmune diabetes.
Cathepsin L mRNA Expression in Spontaneous T1D of
NOD Mice
However, it is still unclear whether cathepsin L has an effect on
the onset of autoimmne diabetes in NOD mice. It is well known
that a considerable proportion of non-diabetic mice are included
among NOD littermates [25,26]. Thus, we analyzed the cathepsin
L mRNA levels of purified CD8
+ T cells from peripheral blood
lymphocytes (PBLs) of non-diabetic and diabetic NOD mice from
three to nine months of age. As shown in Figure 6, the expression
of cathepsin L mRNA of CD8
+ T cells from diabetic NOD mice
was significantly higher than that from non-diabetic NOD mice.
However, there was a range of cathepsin L expressions even in
non-diabetic mice. Some differences in the disease development or
onset in NOD littermates may be associated with expression levels
of cathepsin L. By contrast, enhanced expression of granzyme B in
diabetic NOD mice compared with that in non-diabetic NOD
mice could not be found (data not shown). On the other hand,
when we compared the granzyme B expressions of infiltrating
CD8
+ T cells in the pancreas tissues between non-diabetic and
diabetic NOD mice by flow cytometry, significantly higher
granzyme B expression of diabetic pancreatic CD8
+ T cells was
observed in diabetic NOD mice (Figure S6). These findings
suggest that cathepsin L expression in CD8
+ T cells of peripheral
blood dose not strictly reflect the pathogenesis of autoimmune
diabetes in NOD mice, but it may be one of helpful tools for
diagnosis of T1D as well as the effective strategy by targeting
cathepsin L gene.
Discussion
Although type-1 diabetes can be controlled by insulin injections,
individuals who develop the disease may suffer long-term
complications that include blindness, kidney failure and premature
vascular disease leading to early death [27,28]. The disease is
Figure 4. Effect of CatL-inh on Cytotoxic CD8
+ T Cells. (A) Enzymatic activity of cathepsin L of activated CD8
+ T cells from NOD mice was
detected by confocal microscopic analysis. Purified CD8
+ T cells were stimulated for 24 hours with PMA and ionomycin and then stained with Magic
Red
TM (red) and FITC-conjugated anti-CD8 mAb (green). Original magnification, 6306. (B) Granzyme B expressions of CD8
+ T cells stimulated with
PMA and ionomycin for 24 hours in the presence of CatL-inh were detected by flow cytometric analysis. (C) DPPI enzymatic activities of CD8
+ T cells
from NOD mice were measured. PMA/ionomycin-stimulated CD8
+ T cells were incubated with or without CatL-inh. The activities were shown as
relative fluorescence units to the negative control samples. (D) Cytolytic activity of CD8
+ T cells against enriched islet cells were evaluated by
51Cr
release assay. PMA/ionomycin-stiumlated CD8
+ T cells were incubated with
51Cr-labeled target cells for 6 hours in the presence of CatL-inh (0, 5, and
50 mM). E:T, effector/target. Data are shown as means 6 s.d. of triplicate wells. *, P,0.05, and **, P,0.01.
doi:10.1371/journal.pone.0012894.g004
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understand pathogenic mechanisms to design effective immuno-
therapeutic preventions. These results demonstrate that cathepsin
L, which has been thought to be an antigen-processing enzyme,
plays a critical role in the peripheral immune system.
Cathepsin L functions under the acidified conditions in the
endosome, and plays an important role in the DPPI signaling
events in CD8
+ T cells. It is well known that cathepsin L is
involved in the proteolysis of MHC class II-associated invaliant
chain (Ii) and the antigen presentation in cortical thymic epithelial
cells [29–31]. In this study, it was demonstrated that cathepsin L
has a pivotal effect at the upstream of granzyme B on cytotoxicity
of CD8
+ T cells in the development of T1D other than the
maintenance of Treg cells in the periphery and the thymic
selection. Two reports using cathepsin L-deficient mice focused on
Treg cells which control autoimmune diabetes in NOD mice
[10,32]. Both papers showed that the expression of cathepsin L
was not required for the disease induction. However, there was a
Figure 5. In Vivo Therapeutic Effects of Cathepsin L Gene Targeting on T1D. (A) CY-treated NOD mice were administered with control siRNA
or CatL siRNA. The blood glucose level was measured weekly. (B) Cathepsin L mRNA expressions of PLN CD8
+ T cells were detected by real-time PCR.
(C) Histopathological analysis of pancreas tissues was shown. Results are representative of 4 or 5 mice in each group. (D) Histological score of islets
from control (n=4), control siRNA (n=5) or CatL siRNA-treated (n=5) NOD mice. Data are shown as the histological score of individual islets. (E)
Expression of CD44 on CD8
+ T cells was analyzed by flow cytometry. The results are representative of three mice in each group. (E) DPPI mRNA
expressions of CD8
+ T cells in PLNs were analyzed by real-time PCR. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0012894.g005
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CD25-depleted control and CD25-depleted Cat-L
2/2 splenocytes-
transferred recipients [10,32]. We speculate that Treg cells play an
important role in the disease induction or onset of autoimmune
diabetes in NOD mice, and that the development or severity of the
disease may be attributed to other immune cells including CD8
+ T
cells in addition to the Treg cells. Moreover, although significantly
increased Treg cells in cathepsin L-deficient NOD mice were
detected, there was no difference in the Treg cell number of PLNs
between CY and CY+CatL-inh-treated NOD mice in our
experiment. As for the discrepancy, the cathepsin L inhibitor
might be effective for peripheral T cells, but not T cell
differentiation including Treg cells in the thymus. The effective-
ness may depend on the dose, time span, or timing of CatL-inh
administration, while the weakness of the treatment with specific
CatL-inh is that the metabolic time is considerably short in vivo.
Within approximately 24 hours, the effectiveness had disappeared
in the animal’s bodies. In addition, it was reported that there was
an effect of cathepsin L inhibition using CatL-inh on antigen
processing in the peripheral lymphoid tissues [33]. In our study
using CatL-inh and siRNA of cathepsin L, although we focused on
CD8
+ T cells, possible roles in other immune cells besides CD8
+ T
cells should be researched.
As for the adverse effects of injection of cahtepsin L inhibitor,
when body weight, health condition, and a histopahtological
examination of all organs from CatL-inh-administerred mice was
checked, there was no significant change. This suggests that the
CatL-inh has no toxicity or side effects, and the application may be
clinically useful. Also the administration of siRNA targeting
cathepsin L genes using athelocollagen may have a temporary
effect on the peripheral T cells. It is possible that the siRNA might
not have any effect on the gene-knockdown in the thymus. When
atelocollagen, which is positively charged, interacts with the
negatively charged siRNA duplex, a siRNA/atelocollagen com-
plex is formed. This is a nanosize particle with a diameter of 100–
300 nm. The siRNA/atelocollagen complex was highly stable
against nucleases and a prolonged release of genes and
oligonucleotides without the digestion of RNase [34]. Additionally,
it was confirmed that regarding to specificity for cathepsin L
siRNA, there was a reduction of cathepsin L mRNA of CD8
+ T
cells in PLN from cathepsin L siRNA-treated NOD compared
with that from control NOD mice (relative expression to b-actin
mRNA; control siRNA: 3.62610
23, cathepsin L siRNA:
0.48610
23).
A previous report showed that a reduced number of CD4
+ T
cells in the thymus and periphery of cathepsin L deficient mice was
observed, and that CD8
+ T cells in the deficient mice were
relatively increased [29]. Cathepsin L was found to be necessary
for invariant chain (Ii) degradation in cortical thymic epithelial
cells [29]. The degradation of Ii is known to be a critical step in
MHC class II-restricted antigen presentation that is closely related
with CD4
+ T cell differentiation [35,36]. In addition to the
function of cathepsin L in central tolerance of thymus, we propose
that a significantly upregulated cathepsin L activity in cytotoxic
CD8
+ T cells from NOD mice might play a critical role in the
pathogenesis of T1D. It is known that CD8
+ T cells as well as
CD4
+ T cells are pivotal effector cells for rapid destruction of
pancreatic b-cells in CY-induced T1D [37]. In our experiment,
the cytotoxic activity of NOD CD8
+ cells from spleen against
enriched islet cells from NOD pancreas was significantly reduced
by the addition of CatL-inh. Splenic CD8
+ T cells including a very
low number of b cell antigen-specific CD8
+ T cells in NOD mice
were stimulated with PMA and ionomycin, and used for in vitro
CTL assay. The antigen-specificic CTL activity of CD8
+ T cells in
development of autoimmune diabetes of NOD mice remains
unsolved.
On the other hand, it would be helpful for diagnosis of
spontaneous diabetes in NOD mice to measure cathepsin L
expression in the peripheral T cells. Under three months of age,
there was no change in the cathepsin L expression. In addition, we
have confirmed that the expression of cathepsin L mRNA of CD8
+
T cells in peri-pancreatic LN was significantly enhanced compared
with that of the other immune cells including CD4
+T cells, Treg
cell, B cells, and dendritic cells. Those findings suggested that
cathepsin L in CD8
+ T cells might be activated at an advanced
stage of the disease in NOD mice. However, it is still unclear why
cytotoxic activity of CD8
+ from NOD mice could be upregulated
via the axis of cathepsin L, DPPI, and granzyme B. In addition, we
should pay attention for using the mRNA level of cathepsin L in
the peripheral CD8
+ T cells as the level dose not strictly reflect the
onset or development of autoimmune diabetes in NOD mice.
Further investigation would be required for the clinical application
in human patients.
Foxp3-expressing CD4
+ thymus-derived naturally occurring
Treg cells play an indispensable role in the maintenance of self-
tolerance and immune homeostasis [38,39]. They are potent
suppressors of organ-specific autoimmunity such as T1D,
inflammatory bowel disease, and autoimmune gastritis [40].
Multiple reports have implicated Treg cells in the prevention of
T1D [41,42]. In aged NOD mice, T1D resistance has been
correlated with the expansion of Treg cells with regulatory activity
within inflamed pancreatic lymph nodes [43]. Furthermore, it was
demonstrated that Foxp3-deficient NOD mice, which are deficient
in Treg cells, display an increased incidence and earlier onset of
T1D compared with control NOD mice [44]. Administration of
high-dose CY to prediabetic NOD mice leads to rapid
synchronous onset of T1D (11), and transfer of lymphocytes from
syngenic non-diabetic NOD mice after CY treatment protects
from T1D onset [12]. As for a cellular mechanism for CY-induced
T1D in NOD mice, it was reported that the onset of CY-induced
T1D is associated with a reduction of Treg cells [13]. It is possible
that a reduction of Treg cells in NOD mice by CY injection might
trigger up-regulated cathepsin L activity following cytotcoxicity of
Figure 6. Cathepsin L Expression of CD8
+ T Cells of NOD Mice.
The mRNA expressions of cathepsin L of purified CD8
+ from PBLs
from non-diabetic and diabetic NOD mice were analyzed by real-time
PCR. Mice exceeding 250 mg/dl blood glucose were considered
diabetic. Data are shown as means 6 s.d. of 5 to 10 mice in each group
*, P,0.05.
doi:10.1371/journal.pone.0012894.g006
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+ T cells against pancreatic b-cells through unknown
molecular mechanisms.
Our previous report indicated that cathepsin S inhibitor can
prevent Sjogren’ syndrome which is one of the organ-specific
autoimmune diseases found in salivary and lacrimal glands [8].
Moreover, it was demonstrated that impairment of Ii degradation
and diminished collagen-induced arthritis were observed in
cathepsin S-deficient mice [45]. In the case of a cathepsin S
inhibition or deficiency, the protection of autoimmune response
seems to be due to modulation of antigen presentation. In the
present study, there was no observation of therapeutic effect of
cathepsin S inhibitor on CY-induced T1D in NOD mice. This
implies that lysosomal proteases such as cathepsin L and S play a
critical role in each step of pathogenesis for autoimmune diseases
via complex molecular mechanisms. Careful attention should be
paid to the therapeutic effects of cathepsin L inhibition on the
immune system in the treatment of autoimmune diabetes, the
pathogenesis of which is dependent on CD8
+ T cells. Targeting
these CD8
+ T cells using cathepsin L inhibitor could be a strategy
for the prevention and cure of diabetes in the near future.
Taken together, the results of the experiments presented in this
report show that treatment with cathepsin L inhibition prevents
the cytotoxic CD8
+ T cell response in autoimmune diabetes NOD
mice via inhibiting granzyme B activation. These data point to
cathepsin L as a novel regulatory mechanism of cytotoxicity,
suggesting a potential use of cathepsin L inhibition including
siRNAs delivery as a new therapeutic target in autoimmune
diabetes.
Materials and Methods
Ethics
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the University of Tokushima
(toku09021).
Mice and Treatment
NOD mice were reared in our specific pathogen-free mouse
colony and given food and water ad libitum. Experiments were
humanely conducted under the regulation and permission of the
Animal Care and Use Committee of the University of Tokushima,
Tokushima, Japan. Prediabetic (7 to 8-weeks-old) female NOD
mice were intraperitoneally injected twice with 4 mg cyclophos-
phamide (CY).
Cathepsin Inhibitors
Specific inhibitors for cathepsin B (CA074), cathepsin L
(Clik148 and Clik195), and cathepsin S (Clik60) were developed
with the help of computer-graphic modeling based on the stereo-
structure [46]. We administered the cathepsin inhibitors after the
second injection of CY. In detail, 7 to 8-weeks-old prediabetic
NOD mice were intraperitoneally injected with CY (4 mg per
mouse) once per week for two weeks. At 9 to 10-weeks-old,
cathepsin inhibitors were intraperitoneally administered (0.1 mg
per mouse) every two days for four weeks. We sacrificed the mice
for analysis at 13 to 14-weeks-old.
Assessment of Diabetes
The blood glucose levels and the urine glucose were monitored
weekly with a Glucometer (Kodama, Tokyo, Japan) using 50 ml
blood from the tail vein, and with Keto-Diastix (Bayer-Sankyo
Co., Ltd., Tokyo, Japan), respectively.
Histology
All organs were removed from the mice, fixed with 4%
phosphate-buffered formaldehyde (pH 7.2) and prepared for
histological examination. The sections were stained with hema-
toxylin and eosin (H&E). For semiquantitative evaluation of
infiltration, histological analysis using sections containing five or
more islets was performed as previously described [47]. In brief,
the degree of cellular infiltration was scored from 0 to 5 as follows:
0=no inflammation; 1=infiltrates in small foci at the islet
periphery; 2=infiltrates surrounding the islets (peri-insulitis);
3=intraislet infiltration ,50% of the islet, without islet derange-
ment; 4=extensive infiltration, =50% of the islet, cell destruction
and prominent cytoarchitectural derangement; 5=islet atrophy
because of b cell loss. The evaluation was carried out by three
pathologists in a blinded manner.
Flow Cytometric Analysis
Surface markers on lymphocytes in pancreatic lymph nodes
(PLNs) and pancreas were identified by mAbs with BD FACSCant
flow cytometer (Beckman Coulter, Inc., Miami, FL). Rat mAbs to
FITC-, PE-conjugated anti-CD8 and CD4 mAbs (eBioscience,
San Diego, CA) were used. For detection of T cell activation
markers, PE-Cy5-conjugated anti-CD44 mAbs (eBioscience) were
used. Intracellular Foxp3 and granzyme B (eBioscience) expres-
sions with an intracellular Foxp3 detection kit (eBioscience) were
analyzed according to the manufacturer’s instructions. Enzymatic
activities of cathepsin L were assessed using Magic Red
TM
cathepsin detection kit for cathepsin L (Immunochemistry
Technologies, LLC, Bloomington, MN). Briefly, lymphocytes
were incubated with Magic Red
TM fluorogenic substrates of
cathepsin L according to the manufacturer’s instructions. The red
fluorescence was detectable as a result of intracellular enzymatic
cleavage. The data were analyzed with FlowJo FACS analysis
software (Tree Star).
Cathepsin L Activity Detection Assay
Cathepsin L activity was assayed in the thymus and PLNs from
CY-treated and control NOD mice using a cathepsin L activity
assay kit (BioVision, Mountain View, CA). Briefly, 10 mg
cytoplasmic lysates of thymus and PLNs were incubated with
cathepsin L substrates labeled with amino-4-trifluoromethyl
coumarin (AFC) at 37uC for an hour. The AFC cleaved by
cathepsin L was read with a fluorometric microplate reader
(Tecan, Crailsheim, Germany) at excitation and emission
wavelengths of 400 nm and 505 nm.
Real-time Quantitative Reverse-transcription-polymerase
Chain Reaction (Real-time PCR)
CD8
+ cells, CD4
+ cells, CD4
+CD25
+ cells, B220
+ cells and
CD11c
+ cells were prepared from PLNs by positive selection using
anti-CD8, CD4, CD25, B220 (eBioscience) and CD11c (MBL
International,Woburn,MA)antibodies,andmagneticbeads(Dynal
Biotech, Oslo, Norway). Total RNA was extracted using TRIzol
reagent (Invitrogen, Carlsbad, CA) and reverse transcribed.
Transcript levels of cathepsin L, DPP1 and b-actin were detected
using PTC-200 DNA Engine Cycler (BioRad) with SYBR Premix
Ex Taq (Takara, Kyoto, Japan). Primer sequences were as follows:
cathepsin L: forward, 59-GTGGACTGTTCTCACGCTCA-39
and reverse, 59-TATCCACGAACCCTGTGTCA-39, DPPI: for-
ward, 59-TCTGTCAATGAGTGAGCTGTGTCAA-39 and re-
verse, 59-TGCGCTCATGTGTGTATGGAAG-39 and b-actin:
forward, 59- AAATCTGGCACCACACCTTC -39 and reverse, 59-
AGAGGCGTACAGGGATAGCA -39.
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The frozen sections of pancreas tissues from control and CY-
treated NOD mice were fixed with cold acetone, blocked with
M.O.M.
TM blocking reagent (Vector Laboratories, Inc., Burlin-
game, CA), and then stained with the antibodies FITC-conjugated
antibody to CD8 (eBioscience) and biotinylated antibody to CD4
(BioLegend, San Diego, CA) for over night. After washes in PBS,
the sections were stained with Alexa Fluor 488 goat anti-FITC
IgG and Alexa Fluor 568-conjugated streptavidin (Invitrogen,
Carlsbad, CA) for 40 minutes. The nuclear DNA was stained with
49,6-diamino-2-phenylindole dihydrochloride (DAPI) (Invitrogen).
The sections were visualized with a laser scanning confocal
microscope (Carl Zeiss) at a magnification of 4006 or 6306.
Quick Operation Version 3.2 (Carl Zweiss) for imaging acquisition
and Adobe Photoshop CS2 (Adobe System) for image processing
was used.
Cell Purification
For purification of CD8
+ subset, lymphocytes in pancreas and
PLNs were treated for 30 min at 4uC with mAbs specific for CD4,
CD25, CD11c, NK1.1, B220, and MHC class II (eBioscience),
and then CD8
+ T cells were isolated by negative selection with
magnetic beads (Dynal).
Culture Conditions
Cells were cultured in RPMI 1640 containing 10% FCS, L-
glutamine, penicillin/streptomycin and 2-mercaptoethanol in 96-
well round-bottom microtiter plates stimulated with (0.5,5 ng/ml)
PMA and 500 ng/ml ionomycin (SIGMA, St. Louis, MO).
In Vitro Cathepsin L Activity Detection Assay
Cathepsin L activity of CD8
+ T cells stimulated with PMA and
ionomycin (IM) was assessed by confocal microscopic analysis
using a Magic Red
TM cathepsin detection kit. In brief, CD8
+ T
cells were stimulated with PMA and IM for 24 hours. Cells were
stained with Magic Red
TM according to the manufacture’s
instructions. After staining, cells were deposited onto poly-L-
lysine-coated glass slides and were fixed with 0.25 to 1%
paraformaldehyde. Subsequently, cells were stained with anti-
CD8 mAb and visualized with a laser scanning confocal
microscope. A 6361.4 oil DIC objective lens was used.
DPPI Activity Assay
DPPI activity was assayed by the liberation of the fluorescent
leaving group, 7-amino-4-ethyl coumarin (AMC), and measured
as increase in fluorescence using a fluorometer. Briefly, purified
CD8
+ T cells were stimulated with PMA/IM in the presence of
cathepsin inhibitor (10
26 M) for 40 hours. Cell extracts were
added to H-Gly-Arg-AMC in assay buffer (25 mM MES, 50 mM
NaCl, 5 mM DTT, pH 6.0) and incubated for 1 hour at 37uC.
After incubation, substrate cleavage was measured by fluoropho-
tometer at excitation and emission wavelengths of 380 nm and
460 nm.
Cytotoxic Assay
For target cells, the enriched islets were obtained from NOD
mice at 4-weeks-old as previously described [48,49]. Purified
CD8
+ T cells as effector cells in spleen from NOD mice were
stimulated with PMA/IM in the presence of cathepsin L inhibitor
(0, 5, and 50 mM) for 24 hours. Maximum cytotoxicity was
induced by 0.1% Triton X.
51Cr (Perkin Elmer, Wellesley, MA)-
labeled target cells were incubated with the effector cells for
6 hours at the indicated E:T ratios.
51Cr release of the
supernatants was measured with a g-scintillation counter (Aloka,
Tokyo, Japan). Corrected % lysis was calculated as: corrected %
lysis=1006 (test
51Cr released – spontaneous
51Cr released)/
(maximum
51Cr released - spontaneous
51Cr released).
In Vivo Treatment with Cathepsin L siRNA
Small interfering RNA (siRNA) of cathepsin L and negative
control (B-bridge International, Inc., Sunnyvale, CA) were used
for analysis of in vivo therapeutic effects on the T1D in CY-treated
NOD mice. Sequences of the oligonucleotide were as follows:
cathepsin L: 59-GAGCGAUAUGGGAGAAGAATT-39 and neg-
ative control: 59-ATCCGCGCGATAGTACGTA-39. Briefly,
equal volumes of atelocollagen [50] (Koken, Tokyo, Japan) were
combined with siRNA solution and mixed by rotating at 4uC for
20 mins. The cathepsin L siRNA/atelocollagen complexes or
negative control siRNA/atelocollagen complexes were i.p. admin-
istered into CY-treated NOD mice at doses of 5 nmol/mouse/
twice a week.
Statistical Test
The Student’ t test was used for statistical analysis. Values of
p,0.05 were considered as significant.
Supporting Information
Figure S1 (A) Effect of Cat-L and S inhibitors on antigen
processing and presentation. Splenic CD4+ T cells from OVA-
specific T cell receptor transgenic mice (OT-II) were labeled with
carboxyfluorescein diacetate succinimidyl ester (CFSE), and co-
cultured with T cell-depleted spleen cells as APCs from B6 mice in
the presence of OVA protein with or without CatL-inh or CatS-
inh for 3 days. (B) Proliferation to OVA was evaluated by divided
cells (%). Data are shown as means 6 s.d. of triplicate wells
*, P,0.05, **, P,0.01. Results are representative of two
independent experiments.
Found at: doi:10.1371/journal.pone.0012894.s001 (0.39 MB TIF)
Figure S2 The mRNA expressions of cathepsin L in PLN cells
from C57BL/6 mice. The mRNA expressions of cathepsin L in
purified CD8+ T cells, CD4+ T cells, CD25+CD4+ T cells, B220+
B cells and CD11c+ dendritic cells of PLNs from C57BL/6 mice
were detected by real-time PCR. Data are shown as means 6 s.d.
of triplicate wells, and representative of three mice.
Found at: doi:10.1371/journal.pone.0012894.s002 (0.20 MB
TIF)
Figure S3 Evaluation of toxic effect of cathepsin L inhibitor on
CD8+ T cells. CD8+ T cells from NOD mice were incubated with
CatL-inh (10-5 M) for 24 hours. Apoptotic or necrotic cells were
detected with annexin-V and propidium iodide (PI) staining by
flow cytometry. Results are representative of three independent
experiments.
Found at: doi:10.1371/journal.pone.0012894.s003 (0.63 MB TIF)
Figure S4 The toxic effect of CatL-inh on enriched pancreatic
islet cells. (A) The islet cells were enriched from the pancreas of
NOD mice, and then stained with anti-insulin mAb (HyTest Ltd.
Turku, Finland) and Alexa568-conjugated mouse IgG (H+L) as
the secondary antibody. The nuclei were stained with DAPI.
Insulin-producing cells (red) were detected by confocal microscop-
ic analysis. Results are representative of two independent
experiments. (B) The islet cells were incubated with CatL-inh (0,
10-6, and 10-5 M) for 24 hours. Apoptotic or necrotic cells were
detected with annexin-V and propidium iodide staining by flow
cytometry. Results are representative of three independent
experiments.
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Figure S5 The population of PLN cells from the mice
administered with control siRNA or CatL siRNA. The graph
shows the mean frequency of CD8+ T cells, CD4+ T cells, B220+
B cells and CD11c+ dendritic cells. Data are shown as means 6
s.d. of 3 mice.
Found at: doi:10.1371/journal.pone.0012894.s005 (0.21 MB TIF)
Figure S6 Granzyme B expression of pancreatic CD8+ T cells
from non-diabetic and diabetic NOD mice was analyzed by flow
cytometric analysis. The result is representative of two indepen-
dent experiments.
Found at: doi:10.1371/journal.pone.0012894.s006 (0.47 MB TIF)
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